1 August 2022 false Taxfiler 2024.5 09964324business:PrivateLimitedCompanyLtd2022-08-012023-07-31 099643242022-07-31 099643242022-08-012023-07-31 09964324business:AuditExemptWithAccountantsReport2022-08-012023-07-31 09964324business:FilletedAccounts2022-08-012023-07-31 099643242023-07-31 09964324business:Director12022-08-012023-07-31 09964324business:Director32022-08-012023-07-31 09964324business:RegisteredOffice2022-08-012023-07-31 099643242022-07-31 09964324core:WithinOneYear2023-07-31 09964324core:WithinOneYear2022-07-31 09964324core:AfterOneYear2023-07-31 09964324core:AfterOneYear2022-07-31 09964324core:ShareCapitalcore:PreviouslyStatedAmount2023-07-31 09964324core:ShareCapitalcore:PreviouslyStatedAmount2022-07-31 09964324core:SharePremiumcore:PreviouslyStatedAmount2023-07-31 09964324core:SharePremiumcore:PreviouslyStatedAmount2022-07-31 09964324core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-07-31 09964324core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2022-07-31 09964324core:PreviouslyStatedAmount2023-07-31 09964324core:PreviouslyStatedAmount2022-07-31 09964324business:SmallEntities2022-08-012023-07-31 09964324countries:EnglandWales2022-08-012023-07-31 09964324core:PlantMachinery2022-08-012023-07-31 09964324core:MotorVehicles2022-08-012023-07-31 09964324core:FurnitureFittings2022-08-012023-07-31 09964324core:ComputerEquipment2022-08-012023-07-31 09964324core:PlantMachinery2022-07-31 09964324core:MotorVehicles2022-07-31 09964324core:FurnitureFittings2022-07-31 09964324core:ComputerEquipment2022-07-31 09964324core:PlantMachinery2023-07-31 09964324core:MotorVehicles2023-07-31 09964324core:FurnitureFittings2023-07-31 09964324core:ComputerEquipment2023-07-31 09964324core:AdditionsToInvestments2023-07-31 09964324core:RevaluationsIncreaseDecreaseInInvestments2023-07-31 09964324core:DisposalsRepaymentsInvestments2023-07-31 09964324core:AcceleratedTaxDepreciationDeferredTax2023-07-31 09964324core:AcceleratedTaxDepreciationDeferredTax2022-07-31 09964324core:RevaluationInvestmentPropertyDeferredTax2023-07-31 09964324core:RevaluationInvestmentPropertyDeferredTax2022-07-31 099643242021-07-31 099643242021-08-012022-07-31 iso4217:GBP xbrli:pure
Company Registration No. 09964324 (England and Wales)
DAWN PHARMA GROUP LTD Unaudited accounts for the year ended 31 July 2023
DAWN PHARMA GROUP LTD Unaudited accounts Contents
Page
- 2 -
DAWN PHARMA GROUP LTD Company Information for the year ended 31 July 2023
Directors
Ameer Singh Bahl Karim Kalaf
Company Number
09964324 (England and Wales)
Registered Office
189 Brompton Road London SW3 1NE
Accountants
Project H Limited Accountants Beadle House Bull Plain Hertford Hertfordshire SG14 1DT
- 3 -
DAWN PHARMA GROUP LTD Statement of financial position as at 31 July 2023
2023 
2022 
Notes
£ 
£ 
Fixed assets
Tangible assets
537,899 
567,103 
Investments
4,303,345 
512,245 
4,841,244 
1,079,348 
Current assets
Inventories
19,055 
- 
Debtors
515,871 
370,708 
Cash at bank and in hand
3,685 
3,735 
538,611 
374,443 
Creditors: amounts falling due within one year
(1,085,079)
(1,232,721)
Net current liabilities
(546,468)
(858,278)
Total assets less current liabilities
4,294,776 
221,070 
Creditors: amounts falling due after more than one year
(135,505)
(111,214)
Provisions for liabilities
Deferred tax
(1,008,418)
(92,865)
Net assets
3,150,853 
16,991 
Capital and reserves
Called up share capital
265 
212 
Share premium
399,567 
- 
Profit and loss account
2,751,021 
16,779 
Shareholders' funds
3,150,853 
16,991 
For the year ending 31 July 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 4 October 2023 and were signed on its behalf by
Ameer Singh Bahl Director Company Registration No. 09964324
- 4 -
DAWN PHARMA GROUP LTD Notes to the Accounts for the year ended 31 July 2023
1
Statutory information
DAWN PHARMA GROUP LTD is a private company, limited by shares, registered in England and Wales, registration number 09964324. The registered office is 189 Brompton Road, London, SW3 1NE.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
25% Straight line
Motor vehicles
10% Reducing balance
Fixtures & fittings
25% Reducing balance
Computer equipment
25% Reducing balance
4
Tangible fixed assets
Plant & machinery 
Motor vehicles 
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At cost 
At cost 
At 1 August 2022
350,746 
149,215 
- 
103,815 
603,776 
Additions
12,575 
- 
1,180 
217 
13,972 
At 31 July 2023
363,321 
149,215 
1,180 
104,032 
617,748 
Depreciation
At 1 August 2022
15,527 
4,974 
- 
16,172 
36,673 
Charge for the year
7,541 
14,922 
295 
20,418 
43,176 
At 31 July 2023
23,068 
19,896 
295 
36,590 
79,849 
Net book value
At 31 July 2023
340,253 
129,319 
885 
67,442 
537,899 
At 31 July 2022
335,219 
144,241 
- 
87,643 
567,103 
- 5 -
DAWN PHARMA GROUP LTD Notes to the Accounts for the year ended 31 July 2023
5
Investments
Subsidiary undertakings 
Other investments 
Total 
£ 
£ 
£ 
Valuation at 1 August 2022
11,888 
500,357 
512,245 
Additions
1,100 
- 
1,100 
Fair value adjustments
3,800,000 
- 
3,800,000 
Disposals
(10,000)
- 
(10,000)
Valuation at 31 July 2023
3,802,988 
500,357 
4,303,345 
Our investment in Genedrip Limited, a subsidiary, has been revalued at £3,800,000 based on an evaluation by a 3rd part subscriber.
6
Debtors
2023 
2022 
£ 
£ 
Amounts falling due within one year
VAT
11,955 
- 
Trade debtors
291,574 
167,206 
Amounts due from group undertakings etc.
200,000 
200,000 
Accrued income and prepayments
12,342 
3,502 
515,871 
370,708 
7
Creditors: amounts falling due within one year
2023 
2022 
£ 
£ 
VAT
- 
11,195 
Obligations under finance leases and hire purchase contracts
28,282 
- 
Trade creditors
354,122 
514,371 
Amounts owed to group undertakings and other participating interests
535,342 
687,773 
Taxes and social security
19,257 
4,174 
Other creditors
78,276 
- 
Loans from directors
64,600 
- 
Accruals
5,200 
15,208 
1,085,079 
1,232,721 
8
Creditors: amounts falling due after more than one year
2023 
2022 
£ 
£ 
Obligations under finance leases and hire purchase contracts
96,988 
- 
Amounts owed to group undertakings and other participating interests
38,517 
111,214 
135,505 
111,214 
- 6 -
DAWN PHARMA GROUP LTD Notes to the Accounts for the year ended 31 July 2023
9
Deferred taxation
2023 
2022 
£ 
£ 
Accelerated capital allowances
58,418 
92,865 
Revaluation of investment property
950,000 
- 
1,008,418 
92,865 
2023 
2022 
£ 
£ 
Provision at start of year
92,865 
- 
(Credited)/charged to the profit and loss account
(34,447)
92,865 
Charged to other comprehensive income
950,000 
- 
Provision at end of year
1,008,418 
92,865 
Deferred tax relating to investments that is measured at fair value in accordance with Section 16 Investment Property, shall be measured using the tax rates and allowances that apply to the sale of the asset.
10
Transactions with related parties
Included within debtors is a balance of £200,000 (2022: £200,000) owed by a connected company. The companies are connected by virtue of common directors. Included within creditors is a balance of £535,342 (2022: £687,773) owed to connected companies. The companies are connected by common directors or control.
11
Average number of employees
During the year the average number of employees was 5 (2022: 6).
- 7 -